SOURCE: Equity Markets Inc

October 28, 2011 09:00 ET

What's Ahead: Today's Economic Outlook - Equity Research on Mylan Inc. and Medicis Pharmaceutical Corporation

MACAU--(Marketwire - Oct 28, 2011) - Today, www.EquityMarketsInc.com announced its research report highlighting Mylan Inc. (NASDAQ: MYL) and Medicis Pharmaceutical Corporation (NYSE: MRX). Full content and research is available at www.EquityMarketsInc.com/research.php?id=MYL+MRX.

Short-term outlooks within US and global economies continue to adjust downward, as US Treasury yields touched their lowest levels in over 65 years. International Monetary Fund downgraded estimates for US growth by 1.0% this year, down from 2.5%. 'Significant downside risks' to the US economy were confirmed by the Federal Reserve pressured by 'strains in global financial markets.'

As the US dollar trades above an eight-month high against the Euro, it highlights a deepening of the Eurozone sovereign debt crisis -- furthered by continued policy inaction from European governments. We expect continued volatility until economic data stabilizes and we see decisive policy action to deal with the Eurozone debt crisis.

Our members are preparing for a turn in tides. Currently, the Credit Suisse Risk Appetite Indicator is at a 30-year low. For the past three occurrences, this level has acted as a leading indicator of large stock market rallies 18 months following.

Equity Markets has reviewed Mylan Inc. for its current position within the healthcare industry. Mylan Inc. and its subsidiaries (Mylan) is a generic and specialty pharmaceutical company, which provides products to customers in more than 150 countries and territories. The Company operates in two segments: Generics and Specialty. The full research report on Mylan Inc. (NASDAQ: MYL) is available here: www.EquityMarketsInc.com/research.php?id=MYL.

Equity Markets has reviewed Medicis Pharmaceutical Corporation for its development within the healthcare industry. Medicis Pharmaceutical Corporation (Medicis) together with its wholly owned subsidiaries, is a specialty pharmaceutical company focusing primarily on helping patients attain a healthy and youthful appearance and self-image through the development and marketing in the United States of products for the treatment of dermatological and aesthetic conditions. The full research report on Medicis Pharmaceutical Corporation (NYSE: MRX) is available here: www.EquityMarketsInc.com/research.php?id=MRX.

About Equity Markets
Our mission at Equity Markets is to be the best source of content and research, while educating, enlightening and informing investors. Equity Markets combines street smart analysts and professional market researchers to provide investors with detailed company profiles and market coverage.

Contact Information